Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: dexamethasone
Drug: liposomal doxorubicin
Drug: cyclophoshamide
Drug: filgrastim

Registration Number: NCT00148317

Lead Sponsor: Weill Medical College of Cornell University

Brief Summary: PRIMARY STUDY OBJECTIVES

* To evaluate the efficacy of the combination of bortezomib, dexamethasone, with and without DOXIL, followed by high-dose cyclophosphamide as a therapy for two different subsets of multiple myeloma patients:

1. Patients post first line therapy

2. Patients with relapsed/refractory disease who are bortezomib-naïve

* To evaluate the safety of the combination of bortezomib and dexamethasone, with and without DOXIL, followed by high-dose cyclophosphamide as therapy for patients with multiple myeloma.

SECONDARY STUDY OBJECTIVES

* To evaluate the role of the combination of bortezomib dexamethasone, with and without DOXIL, followed by high-dose cyclophosphamide on the ability to collect \> 10 x 106 CD34+ cells/kg in \< 7 collections (for both subsets of multiple myeloma patients).

* To evaluate the survival of patients who receive the combination of bortezomib dexamethasone, with and without DOXIL, followed by high-dose cyclophosphamide (for both subsets of patients).

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 38

Inclusion Criteria

Subject must voluntarily sign and understand written informed consent.
Confirmed diagnosis of multiple myeloma as specified by the SWOG criteria and is detailed in Appendix I.
Measurable disease as defined the following:
1. For patients post induction therapy, any measurable paraprotein in the serum or urine and/or any plasmacytoma present on physical exam or imaging.
2. For patients with relapsed/refractory disease, > 0.5 g/dL serum monoclonal protein, > 0.1 g/dL serum free light chains, > 0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s).
Age > or = than 18 years at the time of signing the informed consent form.
Karnofsky performance status> or =70% (>60% if due to bony involvement of myeloma).
Group A (post-induction therapy)- patients who have received only one prior treatment regimen (eg VAD, Thal/Dex, BLT-D, MP, BiRD, or DVd) with at least 20 patients having received a Revlimid based regimen or Group B(>1st line of therapy)- patients with relapsed/refractory multiple myeloma who have received two or more prior treatment regimens .
If the patient is a woman of childbearing age, she must have a negative serum or urine pregnancy test within 7 days of starting study and must use effective contraception throughout the course of the study.
Life expectancy > 12 weeks.
Absolute neutrophil count (ANC)> or = 1500 cells/mm3 (> or = 1000 for patients with bone marrow biopsy displaying > 50% involvement by myeloma)
Platelets count > or = 50,000/mm3 (> or = 30,000 for patients with bone marrow biopsy displaying > 50% involvement by myeloma)
Hemoglobin > 9.0 g/dL
Serum SGOT/AST <3.0 x upper limits of normal (ULN)
Serum SGPT/ALT <3.0 x upper limits of normal (ULN)
Serum creatinine < 2.5 mg/dL or creatinine clearance > 40ml/min
Serum total bilirubin < 1.5 x ULN
Patients must have a MUGA scan with LVEF >50%

Exclusion Criteria

Patients with non-secretory MM (no measurable monoclonal protein, free light chains, and/or M-spike in blood or urine) unless measurable disease is available with imaging techniques such as MRI and PET scan.
Prior treatment with bortezomib.
Peripheral neuropathy of > Grade 2 as defined by CTCAE Version 3.0 (see Appendix II)
History of allergic reactions to compounds containing mannitol, bortezomib, conventional formulation of doxorubicin HCL or the components of DOXIL.
Prior history of other malignancies (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless disease free for ³ 5 years.
NYHA Class III or IV heart disease. History of active unstable angina, congestive heart disease, serious uncontrolled cardiac arrhythmia or myocardial infarction within 6 months.
Female patients who are pregnant or breastfeeding. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.
Known HIV or hepatitis A, B, or C positivity
Active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program.
Any concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place him/her at unacceptable risk, including, but not limited to, uncontrolled hypertension, uncontrolled diabetes, active uncontrolled infection, and/or acute chronic liver disease (i.e., hepatitis, cirrhosis).
No prior anti-myeloma therapy within 2 weeks of treatment initiation.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment Arm	dexamethasone	-
Treatment Arm	liposomal doxorubicin	-
Treatment Arm	cyclophoshamide	-
Treatment Arm	Bortezomib	-
Treatment Arm	filgrastim	-

Primary Outcome Measures

Name	Time	Method
Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate)	Best response at any point during each respective study phase was collected - once after consolidation/prior to mobilization (approximately 6 cycles after start of treatment), and once after mobilization	Myeloma response criteria developed by Bladé et al. was used to categorize response.

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival	Date of progression, assessed from start of trial to Final data cut off date (15 April 2011)	Response was assessed using IMWG guidelines, which for progressive disease are as follows: Increase of \> 25% from lowest response value in any one or more of the following: * Serum M-component and/or (the absolute increase must be \> 0.5 g/dL)\* * Urine M-component and/or (the absolute increase must be \> 200 mg/24 h) * Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be \> 10 mg/dL * Bone marrow plasma cell percentage; the absolute percentage must be \> 10% * Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas * Development of hypercalcaemia (corrected serum calcium \> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder IF starting M protein component is \> 5g/dL, then absolute increase of 1g is sufficient for progression.
Yield of CD34+ Stem Cells	Occurred after mobilization, and prior to Stem cell transplant; a 7 day limit was imposed on stem cell collection	This is the yield of CD34+ stem cells collection after high dose cyclophosphamide.